Please use this identifier to cite or link to this item:
|Title:||Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma||Authors:||Poh, W.
|Issue Date:||23-Mar-2012||Citation:||Poh, W., Wong, W., Ong, H., Aung, M.O., Lim, S.G., Chua, B.T., Ho, H.K. (2012-03-23). Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Molecular Cancer 11 : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1476-4598-11-14||Abstract:||Background: We had previously demonstrated overexpression of fibroblast growth factor receptor-4 (FGFR4) in hepatocellular carcinoma (HCC). However, additional molecular mechanisms resulting in amplified FGFR4 signaling in HCC remain under-studied. Here, we studied the mechanistic role of its co-receptor klotho-beta (KLB) in driving elevated FGFR4 activity in HCC progression.Results: Quantitative real-time PCR analysis identified frequent elevation of KLB gene expression in HCC tumors relative to matched non-tumor tissue, with a more than two-fold increase correlating with development of multiple tumors in patients. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. While transient repression of KLB-FGFR4 signaling decreased protein expression of alpha-fetoprotein (AFP), a HCC diagnostic marker, prolonged inhibition enriched for resistant HCC cells exhibiting increased liver stemness.Conclusions: Elevated KLB expression in HCC tissues provides further credence to the oncogenic role of increased FGFR4 signaling in HCC progression and represents a novel biomarker to identify additional patients amenable to anti-FGFR4 therapy. The restricted tissue expression profile of KLB, together with the anti-proliferative effect observed with KLB-silencing, also qualifies it as a specific and potent therapeutic target for HCC patients. The enrichment of a liver stem cell-like population in response to extended KLB-FGFR4 repression necessitates further investigation to target the development of drug resistance. © 2012 Poh et al; licensee BioMed Central Ltd.||Source Title:||Molecular Cancer||URI:||http://scholarbank.nus.edu.sg/handle/10635/106103||ISSN:||14764598||DOI:||10.1186/1476-4598-11-14|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|2012-klotho_beta_overexpression_novel_target-published.pdf||1.03 MB||Adobe PDF|
checked on Jun 13, 2021
WEB OF SCIENCETM
checked on Jun 4, 2021
checked on Jun 7, 2021
checked on Jun 7, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.